57th American Society of Hematology Annual Meeting

• Published in: The Lancet. Oncology Vol. 17; no. 2; p. 142
• Main Author: Smith, Lan-Lan
• Format: Journal Article Conference Proceeding
• Language: English
• Published: England Elsevier Ltd 01.02.2016; Elsevier Limited
• Subjects: Anemia; Antibodies, Monoclonal - therapeutic use; Antigens; Antineoplastic Agents - therapeutic use; Aurora Kinase A - antagonists & inhibitors; Azepines - therapeutic use; Cancer; Cancer therapies; Chimera; Chimeric antigen receptors; Enzyme inhibitors; fms-Like Tyrosine Kinase 3 - genetics; Fusion Proteins, bcr-abl - antagonists & inhibitors; Hematology; Hematology, Oncology and Palliative Medicine; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Lymphoma, T-Cell, Peripheral - drug therapy; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - therapy; Mutation; Pyrimidines - therapeutic use; Societies, Medical; Society; Staurosporine - analogs & derivatives; Staurosporine - therapeutic use; T-Lymphocytes - transplantation; United States; Denmark; New York; United Kingdom > UK; United States > US
• DOI: 10.1016/S1470-2045(15)00579-3
• ISSN: 1470-2045

CAR T-cells for myeloma B-cell maturation antigen (BCMA) is a protein expressed by normal and malignant plasma cells; James Kochenderfer (National Cancer Institute/National Institutes of Health, Bethesda, MD, USA) presented preliminary results from a phase 1 trial that used chimeric antigen receptor (CAR) T-cells to treat patients with multiple myeloma expressing BCMA. Three patients had a response (two of which had been treated at the highest dose). Because cytokine release syndrome was linked with high baseline disease, further studies will restrict patients to a maximum of 50% disease cells before transfusion.